Related Experiment Video

Updated: Jan 11, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

First-Line Third-Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR-Mutated Non-Small Cell Lung

Wei Du1,2, Anlin Li1,2, Bijing Xiao1,2

  • 1State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center For Cancer Sun Yat-sen University Cancer Center Guangzhou China.

Medcomm
|November 10, 2025
PubMed

Insights

Third-generation EGFR TKIs improve outcomes for advanced EGFR-mutated NSCLC. This Bayesian network meta-analysis compares their efficacy and safety, guiding personalized treatment selection for non-small cell lung cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a significant advancement in treating advanced EGFR-mutated non-small cell lung cancer (NSCLC).
  • A direct comparison of the efficacy and safety profiles of various third-generation EGFR TKIs is currently lacking, hindering optimal treatment selection.

Purpose of the Study:

  • To conduct the first head-to-head comparison of third-generation EGFR TKIs using a Bayesian network meta-analysis.
  • To evaluate and compare the efficacy (progression-free survival, objective response rate, intracranial control) and safety (treatment-related adverse events) of different third-generation EGFR TKIs in advanced EGFR-mutated NSCLC.

Main Methods:

  • A Bayesian network meta-analysis was performed on data from seven randomized controlled trials, including a total of 3012 patients.
  • Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and intracranial control.
  • Safety was assessed by comparing rates of severe treatment-related adverse events (TRAEs) across different third-generation EGFR TKIs.

Main Results:

  • All third-generation EGFR TKIs demonstrated superior progression-free survival (PFS) compared to first-generation TKIs, with no significant differences among the third-gen agents themselves.
  • Furmonertinib showed the highest PFS (HR, 0.82), while aumolertinib provided the best intracranial control (HR, 0.74).
  • Osimertinib and lazertinib offered overall survival benefits over first-gen TKIs. Furmonertinib, aumolertinib, and osimertinib had lower severe TRAEs compared to befotertinib, which had the highest risk (RR, 3.96).

Conclusions:

  • This Bayesian network meta-analysis provides critical head-to-head insights into the comparative efficacy and safety of third-generation EGFR TKIs for advanced EGFR-mutated NSCLC.
  • The findings support personalized selection of third-generation EGFR TKIs based on patient-specific factors, such as the presence of CNS metastases or specific mutation subtypes.
  • Furmonertinib, aumolertinib, and osimertinib appear to offer favorable safety profiles regarding severe TRAEs.
Keywords:
Bayesian network meta‐analysisepidermal growth factor receptorfirst‐linenon‐small cell lung cancertyrosine kinase inhibitors

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
428